Business Description
Ultragenyx Pharmaceutical Inc
NAICS : 325412
SIC : 2834
ISIN : US90400D1081
Total Employee Number:
1,371Compare
Compare
Traded in other countries / regions
RARE.USAUP0.Germany0LIF.UKR2AR34.BrazilRARE.Mexico Index Membership
Russell 1000Russell 3000Russell 2000 IPO Date
2014-01-31Description
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. The company identifies, acquires, develops, and commercializes novel products for the treatment of serious, rare, and ultra-rare diseases, with a focus on debilitating genetic conditions. Its medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged one year and older. Mepsevii is indicated for pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. The company operates across North America, Latin America, Europe, the Middle East and Africa, and Asia-Pacific, with the majority of its revenue generated from North America.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 8.11 | |||||
Equity-to-Asset | -0.23 | |||||
Debt-to-Equity | -0.12 | |||||
Debt-to-EBITDA | -0.08 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | -5.29 | |||||
Beneish M-Score | -2.26 | |||||
WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 9.5 | |||||
3-Year EBITDA Growth Rate | 19.3 | |||||
3-Year EPS without NRI Growth Rate | 16.2 | |||||
3-Year FCF Growth Rate | 13.1 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 17.85 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 12.49 | |||||
9-Day RSI | 16.15 | |||||
14-Day RSI | 20.27 | |||||
3-1 Month Momentum % | 16.67 | |||||
6-1 Month Momentum % | 17.34 | |||||
12-1 Month Momentum % | -14.35 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.73 | |||||
Quick Ratio | 1.56 | |||||
Cash Ratio | 0.83 | |||||
Days Inventory | 159.25 | |||||
Days Sales Outstanding | 72.88 | |||||
Days Payable | 112.39 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -11.2 | |||||
Shareholder Yield % | 0.16 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 83.08 | |||||
Operating Margin % | -73.64 | |||||
Net Margin % | -81.7 | |||||
EBITDA Margin % | -65.9 | |||||
FCF Margin % | -68.88 | |||||
OCF Margin % | -67.62 | |||||
ROA % | -44.47 | |||||
ROIC % | -70.8 | |||||
3-Year ROIIC % | 222.51 | |||||
ROC (Joel Greenblatt) % | -206.59 | |||||
ROCE % | -51.64 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 2.02 | |||||
EV-to-EBIT | -1.53 | |||||
EV-to-EBITDA | -1.64 | |||||
EV-to-Revenue | 1.08 | |||||
EV-to-Forward-Revenue | 0.76 | |||||
EV-to-FCF | -1.56 | |||||
Price-to-GF-Value | 0.32 | |||||
Price-to-Median-PS-Value | 0.13 | |||||
Earnings Yield (Greenblatt) % | -65.36 | |||||
FCF Yield % | -35.04 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:RARE
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Ultragenyx Pharmaceutical Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 717.212 | ||
| EPS (TTM) ($) | -5.84 | ||
| Beta | 1.2212 | ||
| 3-Year Sharpe Ratio | -0.08 | ||
| 3-Year Sortino Ratio | -0.12 | ||
| Volatility % | 66.38 | ||
| 14-Day RSI | 20.27 | ||
| 14-Day ATR ($) | 1.777007 | ||
| 20-Day SMA ($) | 23.18175 | ||
| 12-1 Month Momentum % | -14.35 | ||
| 52-Week Range ($) | 13.81 - 39.8899 | ||
| Shares Outstanding (Mil) | 98.59 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Ultragenyx Pharmaceutical Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Ultragenyx Pharmaceutical Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Annual report for 2026 | 2027-02-18 | In 160 days | ||
| Fourth quarter earnings conference call for 2026 | 2027-02-12 17:00 | In 155 days | ||
| Fourth quarter earnings results for 2026 | 2027-02-12 | In 154 days | ||
| Third quarter earnings conference call for 2026 | 2026-11-04 17:00 | In 55 days | ||
| Third quarter earnings results for 2026 | 2026-11-04 | In 54 days | ||
| Ultragenyx Corporate Update Conference Call | 2026-08-19 18:00 | 25.49 (-0.74%) | ||
| Second quarter earnings conference call for 2026 | 2026-08-04 17:00 | 25.02 (+0.40%) | ||
| Second quarter earnings results for 2026 | 2026-08-04 | 25.02 (+0.40%) | ||
| Goldman Sachs 47th Annual Global Healthcare Conference | 2026-06-09 16:00 | 21.59 (-2.53%) | ||
| General meeting for 2026 | 2026-05-14 08:30 | 26.46 (-0.56%) |
Show
Entries
Ultragenyx Pharmaceutical Inc Frequently Asked Questions
What is Ultragenyx Pharmaceutical Inc(RARE)'s stock price today?
The current price of RARE is $14.30. The 52 week high of RARE is $39.89 and 52 week low is $13.81.
When is next earnings date of Ultragenyx Pharmaceutical Inc(RARE)?
The next earnings date of Ultragenyx Pharmaceutical Inc(RARE) is 2026-11-04 Est..
Does Ultragenyx Pharmaceutical Inc(RARE) pay dividends? If so, how much?
Ultragenyx Pharmaceutical Inc(RARE) does not pay dividend.
Guru Commentaries on NAS:RARE
Amg Frontier Small Cap Growth
Bullish
2025 Q3
AMG Frontier Small Cap Growth Fund
· 119 holdings
What the manager wrote
Ultragenyx develops and manufactures drugs for rare diseases. The company’s current portfolio is growing by approximately 10% annually and is robust enough for the company to achieve cash flow breakeven within a few years. It also has three opportunities for new drug approvals over the next year, each of which has a multi-billion dollar addressable market. We think that given the company’s existing drug portfolio and the large opportunities ahead, Ultragenyx presents an attractive asymmetrical risk-return profile, and we added to our position.
Press Release
Headlines
See More- 1
Sep 03, 2026
Ultragenyx slides amid multiple downgrades on trial setback for Angelman syndrome drug
Seeking Alpha • 10:31am
At a glance: stocks gapping down premarket
Seeking Alpha • 6:37am
Ultragenyx drops on Phase 3 trial failure for Angelman syndrome drug
Seeking Alpha • 12:55am
- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers